Market Cap (In USD)
80.00
Revenue (In USD)
-
Net Income (In USD)
-
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0E-6-2.0E-4
- PE
- -
- EPS
- -
- Beta Value
- -13.762
- ISIN
- US14141D2018
- CUSIP
- 14141D201
- CIK
- 1544238
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. David G. Watumull
- Employee Count
- -
- Website
- https://www.cardaxpharma.com
- Ipo Date
- 2013-03-06
- Details
- Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
More Stocks
-
BYRN
-
SB-PDSafe Bulkers, Inc.
SB-PD
-
VICP
-
0K6OFarfetch Limited
0K6O
-
SKTTanger Inc.
SKT
-
603368
-
AAPLApple Inc.
AAPL
-
CURICuriosityStream Inc.
CURI